Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial
Amanda Johnson(Fairview Health Services), Hisham Abdel-Azim(Loma Linda University Medical Center), Michael A. Pulsipher(Primary Children's Hospital), Eric Anderson(University of California San Diego), Neena Kapoor(St Vincent's Hospital Sydney), Xi Qiao(Ludong University), Christopher C. Dvorak(University of California, San Francisco), Carrie L. Kitko(Vanderbilt University Medical Center), Sonali Chaudhury(Northwestern University), Alice Bertaina(Stanford University), Nahal Lalefar(University of California, San Francisco), Julie‐An Talano(Dana-Farber Cancer Institute), Yuxin Zhao(Huntsman Cancer Institute), Allyson Flower(New York Medical College), Nancy Bunin(University of Iowa), Karely V T. Van Thiel Berghuijs(Huntsman Cancer Institute), J. Gregory Dolan(University of Utah)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|420
A biomarker panel for acute graft-versus-host disease
|Blood|2008|404
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369